Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.
Nathan Bahary, MD, PhD
Advertisement
Articles by Nathan Bahary, MD, PhD
Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.
Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.
Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Bahary on the Prognosis of BRAF-Mutant Colorectal CancerOctober 28th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
4
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
5